Clarithromycin use and risk of death in patients with ischemic heart disease

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Clarithromycin use and risk of death in patients with ischemic heart disease. / Andersen, Søren Skøtt; Hansen, Morten Lock; Norgaard, Mette Lykke; Folke, Fredrik; Fosbøl, Emil Loldrup; Abildstrøm, Steen Z; Raunsø, Jakob; Madsen, Mette; Køber, Lars; Gislason, Gunnar H; Torp-Pedersen, Christian; Andersen, Søren Skøtt; Hansen, Morten Lock; Norgaard, Mette Lykke; Folke, Fredrik; Fosbøl, Emil Loldrup; Abildstrøm, Steen Z; Raunsø, Jakob; Madsen, Mette; Køber, Lars; Gislason, Gunnar H; Torp-Pedersen, Christian.

I: Cardiology, Bind 116, Nr. 2, 01.07.2010, s. 89-97.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Andersen, SS, Hansen, ML, Norgaard, ML, Folke, F, Fosbøl, EL, Abildstrøm, SZ, Raunsø, J, Madsen, M, Køber, L, Gislason, GH, Torp-Pedersen, C, Andersen, SS, Hansen, ML, Norgaard, ML, Folke, F, Fosbøl, EL, Abildstrøm, SZ, Raunsø, J, Madsen, M, Køber, L, Gislason, GH & Torp-Pedersen, C 2010, 'Clarithromycin use and risk of death in patients with ischemic heart disease', Cardiology, bind 116, nr. 2, s. 89-97. https://doi.org/10.1159/000315394, https://doi.org/10.1159/000315394

APA

Andersen, S. S., Hansen, M. L., Norgaard, M. L., Folke, F., Fosbøl, E. L., Abildstrøm, S. Z., Raunsø, J., Madsen, M., Køber, L., Gislason, G. H., Torp-Pedersen, C., Andersen, S. S., Hansen, M. L., Norgaard, M. L., Folke, F., Fosbøl, E. L., Abildstrøm, S. Z., Raunsø, J., Madsen, M., ... Torp-Pedersen, C. (2010). Clarithromycin use and risk of death in patients with ischemic heart disease. Cardiology, 116(2), 89-97. https://doi.org/10.1159/000315394, https://doi.org/10.1159/000315394

Vancouver

Andersen SS, Hansen ML, Norgaard ML, Folke F, Fosbøl EL, Abildstrøm SZ o.a. Clarithromycin use and risk of death in patients with ischemic heart disease. Cardiology. 2010 jul. 1;116(2):89-97. https://doi.org/10.1159/000315394, https://doi.org/10.1159/000315394

Author

Andersen, Søren Skøtt ; Hansen, Morten Lock ; Norgaard, Mette Lykke ; Folke, Fredrik ; Fosbøl, Emil Loldrup ; Abildstrøm, Steen Z ; Raunsø, Jakob ; Madsen, Mette ; Køber, Lars ; Gislason, Gunnar H ; Torp-Pedersen, Christian ; Andersen, Søren Skøtt ; Hansen, Morten Lock ; Norgaard, Mette Lykke ; Folke, Fredrik ; Fosbøl, Emil Loldrup ; Abildstrøm, Steen Z ; Raunsø, Jakob ; Madsen, Mette ; Køber, Lars ; Gislason, Gunnar H ; Torp-Pedersen, Christian. / Clarithromycin use and risk of death in patients with ischemic heart disease. I: Cardiology. 2010 ; Bind 116, Nr. 2. s. 89-97.

Bibtex

@article{1ca4a2007d3e11df928f000ea68e967b,

title = "Clarithromycin use and risk of death in patients with ischemic heart disease",

abstract = "Objectives: To examine whether treatment with clarithromycin was associated with an increased risk of death in patients with preexisting ischemic heart disease (IHD). Methods: Employing nationwide registers, all patients with IHD events from 1997 to 2007 who subsequently claimed prescriptions for dual antibiotic treatment for eradication treatment were identified. The primary endpoint was all-cause mortality. Results: The study included 214,330 individuals with IHD; 5,265 (2.5 %) of these claimed prescriptions for dual antibiotics. Compared with IHD patients not undergoing eradication therapy, no increase in the risk of all-cause mortality was demonstrated (HR 1.02; 95% CI 0.84-1.23, p = 0.87) after 5 years. Conclusions: The use of clarithromycin in the setting of eradication treatment for Helicobacter pylori in patients with IHD was not associated with an increased risk of death.",

author = "Andersen, {S{\o}ren Sk{\o}tt} and Hansen, {Morten Lock} and Norgaard, {Mette Lykke} and Fredrik Folke and Fosb{\o}l, {Emil Loldrup} and Abildstr{\o}m, {Steen Z} and Jakob Rauns{\o} and Mette Madsen and Lars K{\o}ber and Gislason, {Gunnar H} and Christian Torp-Pedersen and Andersen, {S{\o}ren Sk{\o}tt} and Hansen, {Morten Lock} and Norgaard, {Mette Lykke} and Fredrik Folke and Fosb{\o}l, {Emil Loldrup} and Abildstr{\o}m, {Steen Z} and Jakob Rauns{\o} and Mette Madsen and Lars K{\o}ber and Gislason, {Gunnar H} and Christian Torp-Pedersen",

note = "Copyright {\textcopyright} 2010 S. Karger AG, Basel.",

year = "2010",

month = jul,

day = "1",

doi = "10.1159/000315394",

language = "English",

volume = "116",

pages = "89--97",

journal = "Cardiologia",

issn = "0008-6312",

publisher = "S Karger AG",

number = "2",

}

RIS

TY - JOUR

T1 - Clarithromycin use and risk of death in patients with ischemic heart disease

AU - Andersen, Søren Skøtt

AU - Hansen, Morten Lock

AU - Norgaard, Mette Lykke

AU - Folke, Fredrik

AU - Fosbøl, Emil Loldrup

AU - Abildstrøm, Steen Z

AU - Raunsø, Jakob

AU - Madsen, Mette

AU - Køber, Lars

AU - Gislason, Gunnar H

AU - Torp-Pedersen, Christian

AU - Andersen, Søren Skøtt

AU - Hansen, Morten Lock

AU - Norgaard, Mette Lykke

AU - Folke, Fredrik

AU - Fosbøl, Emil Loldrup

AU - Abildstrøm, Steen Z

AU - Raunsø, Jakob

AU - Madsen, Mette

AU - Køber, Lars

AU - Gislason, Gunnar H

AU - Torp-Pedersen, Christian

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Objectives: To examine whether treatment with clarithromycin was associated with an increased risk of death in patients with preexisting ischemic heart disease (IHD). Methods: Employing nationwide registers, all patients with IHD events from 1997 to 2007 who subsequently claimed prescriptions for dual antibiotic treatment for eradication treatment were identified. The primary endpoint was all-cause mortality. Results: The study included 214,330 individuals with IHD; 5,265 (2.5 %) of these claimed prescriptions for dual antibiotics. Compared with IHD patients not undergoing eradication therapy, no increase in the risk of all-cause mortality was demonstrated (HR 1.02; 95% CI 0.84-1.23, p = 0.87) after 5 years. Conclusions: The use of clarithromycin in the setting of eradication treatment for Helicobacter pylori in patients with IHD was not associated with an increased risk of death.

AB - Objectives: To examine whether treatment with clarithromycin was associated with an increased risk of death in patients with preexisting ischemic heart disease (IHD). Methods: Employing nationwide registers, all patients with IHD events from 1997 to 2007 who subsequently claimed prescriptions for dual antibiotic treatment for eradication treatment were identified. The primary endpoint was all-cause mortality. Results: The study included 214,330 individuals with IHD; 5,265 (2.5 %) of these claimed prescriptions for dual antibiotics. Compared with IHD patients not undergoing eradication therapy, no increase in the risk of all-cause mortality was demonstrated (HR 1.02; 95% CI 0.84-1.23, p = 0.87) after 5 years. Conclusions: The use of clarithromycin in the setting of eradication treatment for Helicobacter pylori in patients with IHD was not associated with an increased risk of death.

U2 - 10.1159/000315394

DO - 10.1159/000315394

M3 - Journal article

VL - 116

SP - 89

EP - 97

JO - Cardiologia

JF - Cardiologia

SN - 0008-6312

IS - 2

ER -

ID: 20395185